Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Blenrep
Pharma
GSK raises long-term sales goal—again—despite vaccines woes
After re-adding Blenrep to its portfolio, GSK now expects sales to reach more than £40 billion in 2031. The company's previous target was £38 billion.
Angus Liu
Feb 5, 2025 11:06am
ASH: GSK details Blenrep's survival win against J&J's Darzalex
Dec 9, 2024 1:30pm
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
Nov 14, 2024 9:24am
GSK readopts £3B peak sales estimate for myeloma ADC Blenrep
Jun 17, 2024 3:22pm
GSK axes Blenrep combo studies with SpringWorks' Ogsiveo
Jun 10, 2024 10:20am
ASCO: GSK builds case for Blenrep's return in multiple myeloma
Jun 2, 2024 8:00am
